Aldeyra Therapeutics Inc. (ALDX)’s Financial Results Comparing With Verrica Pharmaceuticals Inc. (NASDAQ:VRCA)

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) and Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) compete against each other in the Biotechnology sector. We will compare them and contrast their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aldeyra Therapeutics Inc. 7 0.00 N/A -1.96 0.00
Verrica Pharmaceuticals Inc. 10 0.00 N/A -1.03 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.


Table 2 shows us Aldeyra Therapeutics Inc. and Verrica Pharmaceuticals Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Aldeyra Therapeutics Inc. 0.00% -80% -70%
Verrica Pharmaceuticals Inc. 0.00% -28.4% -27.5%


The Current Ratio of Aldeyra Therapeutics Inc. is 9.2 while its Quick Ratio stands at 9.2. The Current Ratio of rival Verrica Pharmaceuticals Inc. is 27.7 and its Quick Ratio is has 27.7. Verrica Pharmaceuticals Inc. is better equipped to clear short and long-term obligations than Aldeyra Therapeutics Inc.

Analyst Recommendations

The following table given below contains the ratings and recommendations for Aldeyra Therapeutics Inc. and Verrica Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Aldeyra Therapeutics Inc. 0 0 1 3.00
Verrica Pharmaceuticals Inc. 0 0 0 0.00

$35 is Aldeyra Therapeutics Inc.’s consensus target price while its potential upside is 491.22%.

Insider & Institutional Ownership

Aldeyra Therapeutics Inc. and Verrica Pharmaceuticals Inc. has shares owned by institutional investors as follows: 69.9% and 34.9%. 2.2% are Aldeyra Therapeutics Inc.’s share owned by insiders. On the other hand, insiders owned about 10.2% of Verrica Pharmaceuticals Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aldeyra Therapeutics Inc. 0.92% -10.46% -31.76% -37.94% -19.41% -33.98%
Verrica Pharmaceuticals Inc. 19.18% -0.16% 24.9% 1.92% -30.45% 50.18%

For the past year Aldeyra Therapeutics Inc. has -33.98% weaker performance while Verrica Pharmaceuticals Inc. has 50.18% stronger performance.


Verrica Pharmaceuticals Inc. beats Aldeyra Therapeutics Inc. on 6 of the 7 factors.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.

Verrica Pharmaceuticals Inc. develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790. The company is headquartered in West Chester, Pennsylvania.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.